Silco Pharmaceuticals Limited

DSE:SILCOPHL Stock Report

Market Cap: ৳1.7b

Silco Pharmaceuticals Valuation

Is SILCOPHL undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of SILCOPHL when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: SILCOPHL (BDT16.7) is trading above our estimate of fair value (BDT0.96)

Significantly Below Fair Value: SILCOPHL is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for SILCOPHL?

Key metric: As SILCOPHL is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for SILCOPHL. This is calculated by dividing SILCOPHL's market cap by their current earnings.
What is SILCOPHL's PE Ratio?
PE Ratio40.5x
Earnings৳42.76m
Market Cap৳1.73b

Price to Earnings Ratio vs Peers

How does SILCOPHL's PE Ratio compare to its peers?

The above table shows the PE ratio for SILCOPHL vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average89.6x
ADVENT Advent Pharma
23.5xn/a৳1.6b
AMBEEPHA Ambee Pharmaceuticals
159.3xn/a৳1.7b
TECHNODRUG Techno Drugs
25xn/a৳4.9b
ORIONINFU Orion Infusion
150.6xn/a৳6.4b
SILCOPHL Silco Pharmaceuticals
40.5xn/a৳1.7b

Price-To-Earnings vs Peers: SILCOPHL is good value based on its Price-To-Earnings Ratio (40.5x) compared to the peer average (89.6x).

Price to Earnings Ratio vs Industry

How does SILCOPHL's PE Ratio compare vs other companies in the Asian Pharmaceuticals Industry?

10 CompaniesPrice / EarningsEstimated GrowthMarket Cap
SILCOPHL 40.5xIndustry Avg. 24.0xNo. of Companies75PE020406080100+
10 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: SILCOPHL is expensive based on its Price-To-Earnings Ratio (40.5x) compared to the Asian Pharmaceuticals industry average (24x).

Price to Earnings Ratio vs Fair Ratio

What is SILCOPHL's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

SILCOPHL PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio40.5x
Fair PE Ration/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate SILCOPHL's Price-To-Earnings Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies